Author(s): Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, , Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM,
Abstract Share this page
Abstract Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.
This article was published in Nature
and referenced in Journal of AIDS & Clinical Research